Leonard Alsfeld, MD
Internal Medicine · Charleston, SCNPI 1912346693
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,213 of the $90,899 with a category attached, or 66.2%. 21 manufacturers reported payments, led by Gilead at 57.4% of the total. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $770.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$52K
- Incyte Corporation$26K
- E.r. Squibb & Sons, L.L.C.$6K
- CTI Biopharma Corp.$3K
- Amgen$1K
- National Marrow Donor Program$1K
- plus $868 from 15 others
What the payments were for
- Consulting fees$19,22821%
- Speaking & faculty fees$60,21366%
- Travel & lodging$7,8739%
- Food & beverage$3,1904%
- Education$3820%
- Gifts$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 43 | $52,193 |
| Incyte Corporation | 36 | $25,632 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,284 |
| CTI Biopharma Corp. | 2 | $3,192 |
| Amgen | 1 | $1,372 |
| National Marrow Donor Program | 4 | $1,359 |
| AstraZeneca | 2 | $166 |
| AbbVie | 5 | $107 |
| Astellas Pharma US Inc | 1 | $100 |
| Janssen Scientific Affairs, LLC | 3 | $82 |
| Genmab U.S., Inc. | 2 | $58 |
| Beigene USA, Inc. | 3 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $52 |
| Johnson & Johnson | 1 | $48 |
| Regeneron | 1 | $41 |
| Beone Medicines USA, Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Novartis | 1 | $29 |
| Morphosys, US Inc. | 1 | $24 |
| Legend Biotech USA Inc. | 1 | $21 |
| Epizyme, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,899 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 75 | $1,225,492 |
| PromactaEltrombopag Olamine | 60 | $1,209,717 |
| OjjaaraMomelotinib Dihydrochloride | 20 | $531,006 |
| IdhifaEnasidenib Mesylate | 12 | $410,652 |
| VonjoPacritinib Citrate | 16 | $398,422 |
| IclusigPonatinib Hcl | 18 | $381,611 |
| VenclextaVenetoclax | 110 | $379,982 |
| RezurockBelumosudil Mesylate | 21 | $353,587 |
| RevlimidLenalidomide | 13 | $289,025 |
| Lenalidomide | 14 | $169,188 |
| Deferasirox | 11 | $89,141 |
| PrevymisLetermovir | 11 | $79,063 |
| Posaconazole | 59 | $58,128 |
| EliquisApixaban | 26 | $17,179 |
| Atovaquone | 11 | $8,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $25,632 | $1,225,49275 claims |
| NovartisPromacta | $29 | $1,209,71760 claims |
| AbbVieVenclexta | $107 | $379,982110 claims |
| AstraZenecaSymbicort | $166 | $2,93013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- John CleekCharleston$136K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
- Hardik PatelCharleston$15K
- Mithunan MaheswaranathanCharleston$14K
- Frances HughesCharleston$11K
- Molly McVeyCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.